On November 3, 2023 Hopewell Therapeutics, a biotechnology company with a tissue targeted lipid nanoparticle (ttLNP) platform harnessing unique ionizable lipid chemistry, reported that it will have both an oral and a poster presentation on preclinical data from the Company’s Oncology programs at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting, being held November 1 – 5, 2023, in San Diego, California (Press release, Hopewell Therapeutics, NOV 3, 2023, View Source [SID1234636919]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentations are as follows:

Poster Presentation

Title: Tissue-targeted lipid nanoparticle delivery for mRNA encoding bispecific T-cell engager demonstrated potent antitumor effects on both hematological malignancies and solid tumors
Presenter: Xin Kai, Ph.D., Director of Discovery Biology, Hopewell Therapeutics
Abstract Number: 1358
Date and Time: Saturday, November 4th, 2023, from 9:00 a.m.– 8:30 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Oral Presentation

Title: Tissue-targeted lipid nanoparticle delivery for mRNA encoding bispecific T-cell engager demonstrated potent antitumor effects on both hematological malignancies and solid tumors
Presenter: Xin Kai, Ph.D., Director of Discovery Biology, Hopewell Therapeutics
Abstract Number: 1358
Session: 205b | Rapid-Oral Abstract-Clinical
Date and Time: Saturday, November 4th, 2023, at 12:40 p.m. PDT
Location: Ground Level – Exhibit Hall C – San Diego Convention Center

Posters will be available here at the start of the scientific session.